Last reviewed · How we verify
aglatimagene besadenovec + valacyclovir
Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.
Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics. Used for Metastatic pancreatic cancer, Ovarian cancer.
At a glance
| Generic name | aglatimagene besadenovec + valacyclovir |
|---|---|
| Also known as | CAN-2409 plus prodrug, AdV-tk, CAN-2409 |
| Sponsor | Candel Therapeutics, Inc. |
| Drug class | Oncolytic immunotherapy |
| Target | IL-12 expression; adenovirus replication machinery |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aglatimagene besadenovec is a conditionally replicating adenovirus engineered to express interleukin-12 (IL-12), which enhances anti-tumor immune responses by promoting T-cell activation and infiltration into the tumor microenvironment. Valacyclovir, a nucleoside analog antiviral, is co-administered to fine-tune viral replication dynamics and potentially optimize the immunogenic window. Together, this combination aims to leverage oncolytic virotherapy with immunostimulation for enhanced anti-tumor efficacy.
Approved indications
- Metastatic pancreatic cancer
- Ovarian cancer
Common side effects
- Flu-like symptoms
- Injection site reactions
- Fatigue
- Fever
Key clinical trials
- A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (PHASE2)
- CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (PHASE2)
- Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (PHASE2)
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PHASE3)
- Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (PHASE1)
- GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas (PHASE1)
- Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma (PHASE2)
- Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: